8-K: Philip Morris International and British American Tobacco Reach Global Patent Settlement

Philip Morris International and British American Tobacco have agreed to a global settlement resolving all ongoing patent infringement litigation related to heated tobacco and vapor products.

Summary

• Philip Morris International (PMI) and British American Tobacco (BAT) have reached a global settlement agreement effective February 1, 2024, resolving all ongoing patent infringement litigation between the parties related to heated tobacco and vapor products.
• The settlement includes the dismissal of pending legal proceedings, rescission of an import ban on PMI's heated tobacco products in the U.S., and the discharge of all related injunctions.
• The agreement covers a wide range of products including nicotine and non-nicotine heat-not-burn consumables and devices, as well as e-vapor products and devices, with a substantially worldwide geographical scope.
• Both parties have agreed to mutual releases from past, present, and future claims related to the litigation, patent infringements, and intellectual property rights.
• The settlement also includes covenants not to sue on a perpetual, royalty-free or royalty-bearing basis for certain existing and future heated tobacco and e-vapor products.
• PMI has invested more than $10.5 billion since 2008 to develop and commercialize innovative smoke-free products.
• As of September 30, 2023, PMI's smoke-free products were available in 82 markets, with an estimated 19.7 million adults having switched to IQOS.
• Smoke-free products accounted for approximately 36.2% of PMI's total third-quarter 2023 net revenues.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the resolution of a major legal dispute, allowing for future innovation and growth in the reduced-risk product category. The settlement is a strategic win for both companies.

Positives

• The settlement resolves all ongoing patent litigation, reducing legal uncertainty and costs for both companies.
• The agreement allows both PMI and BAT to innovate and introduce new products without fear of immediate litigation.
• The rescission of the import ban on PMI's heated tobacco products in the U.S. opens up a significant market opportunity.
• The settlement supports PMI's strategy to transition to smoke-free products and end the sale of cigarettes.
• PMI's significant investment in smoke-free products demonstrates a commitment to innovation and harm reduction.

Negatives

• The settlement includes covenants not to sue on a perpetual, royalty-free or royalty-bearing basis, which may limit future revenue potential from certain patents.
• The agreement does not include any monetary provisions, suggesting that neither party received direct financial compensation for past infringements.
• The settlement is complex and includes various terms and conditions, which could lead to future disputes if not carefully managed.

Risks

• The settlement agreement includes potential events of default that could lead to disputes or termination of the agreement.
• Future profitability may be affected if PMI is unsuccessful in commercializing reduced-risk products or if regulations do not differentiate between such products and cigarettes.
• PMI faces risks related to excise tax increases, marketing restrictions, health concerns, litigation, competition, and global economic and political developments.
• The company's future results are subject to the lower predictability of the reduced-risk product category's performance.

Future Outlook

PMI aims to continue innovating in reduced-risk products to further advance Tobacco Harm Reduction and is working to deliver a smoke-free future, evolving its portfolio to include products outside of the tobacco and nicotine sector.

Management Comments

• We are pleased that this matter has been resolved to the mutual satisfaction of both parties, said Jacek Olczak, Chief Executive Officer.
• There is a clear and growing global desire from adults who smoke to choose from a range of smoke-free products, and we believe continued reduced-risk category innovation can accelerate declines in the harms associated with smoking to the benefit of consumers and public health at large as we continue PMIs journey to end the sale of cigarettes.

Industry Context

This settlement is significant in the tobacco industry as it resolves a major patent dispute between two of the largest players, allowing them to focus on innovation and the development of reduced-risk products. It also signals a move towards a future where smoke-free alternatives are increasingly important.

Comparison to Industry Standards

• The settlement between PMI and BAT is a significant event in the tobacco industry, comparable to other major patent disputes that have shaped the competitive landscape.
• While specific details of royalty arrangements are not disclosed, the agreement's focus on future innovation aligns with the industry's broader shift towards reduced-risk products, similar to strategies adopted by other major tobacco companies.
• The investment of $10.5 billion by PMI in smoke-free products is a substantial commitment, comparable to the R&D spending of other major players in the sector, such as Japan Tobacco and Imperial Brands, who are also investing heavily in next-generation products.
• The 36.2% revenue share from smoke-free products for PMI in Q3 2023 is a key metric, and while specific benchmarks vary across companies, it indicates a significant shift in PMI's revenue mix, similar to the trends seen in other companies with a strong focus on reduced-risk products.

Legal Proceedings

• The settlement resolves all ongoing patent infringement litigation between PMI and BAT.
• The settlement includes the dismissal of pending legal proceedings and the rescission of an import ban on PMI's heated tobacco products in the U.S.

Stakeholder Impact

• Shareholders will likely view the settlement positively as it reduces legal uncertainty and allows for future growth.
• Employees may benefit from increased innovation and new product development opportunities.
• Customers may have access to a wider range of reduced-risk products.
• The settlement may have a positive impact on public health by promoting the transition to smoke-free alternatives.

Next Steps

• PMI and BAT will dismiss pending legal proceedings and request rescission of the Limited Exclusion Order.
• Both parties will continue to innovate and introduce new product iterations in the heated tobacco and vapor product categories.
• PMI will continue its journey to end the sale of cigarettes and focus on smoke-free products.

Key Dates

Keywords

patent settlement, Philip Morris International, British American Tobacco, heated tobacco, vapor products, intellectual property, litigation, smoke-free products, IQOS, harm reduction